MULROY DENNIS 4

4 · ANAPTYSBIO, INC · Filed Dec 18, 2025

Form 4

Period: 2025-12-16

CHIEF FINANCIAL OFFICER

Transactions

Exercise/Conversion
Common Stock
2025-12-16$20.16/sh+10,000$201,600→ 25,126 total
Sale
Common Stock
2025-12-16$44.62/sh−9,365$417,821→ 15,761 total
Sale
Common Stock
2025-12-16$45.21/sh−6,360$287,511→ 9,401 total
Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-16−10,000→ 70,600 total
Exercise: $20.16Exp: 2030-07-12→ Common Stock (10,000 underlying)

Footnotes (6)

[F1]Reflects the acquisition of 1,324 shares acquired under the Company's ESPP.
[F2]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.065 to $45.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]The stock option is fully vested.
[F6]In addition to the remaining options to purchase 70,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 339,440 shares of common stock, which options vest according to their terms.

Documents

1 file